Connor, Clark & Lunn Investment Management (CC&L)
PLX icon

Connor, Clark & Lunn Investment Management (CC&L)’s Protalix BioTherapeutics PLX Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-207,275
Closed -$450K – 1756
2026
Q1 		$450K Sell
207,275
-24,818
-11% -$61.6K ﹤0.01% 1333
2025
Q4 		$418K Sell
232,093
-168,305
-42% -$344K ﹤0.01% 1334
2025
Q3 		$889K Sell
400,398
-95,818
-19% -$156K ﹤0.01% 1096
2025
Q2 		$734K Buy
496,216
+13,341
+3% +$27.3K ﹤0.01% 1142
2025
Q1 		$1.24M Buy
+482,875
New +$1.15M 0.01% 882
2024
Q1 		– Sell
-70,990
Closed -$126K – 1677
2023
Q4 		$126K Sell
70,990
-96,546
-58% -$150K ﹤0.01% 1301
2023
Q3 		$278K Buy
167,536
+51,997
+45% +$93.3K ﹤0.01% 1161
2023
Q2 		$231K Sell
115,539
-43,164
-27% -$103K ﹤0.01% 1160
2023
Q1 		$333K Buy
+158,703
New +$278K ﹤0.01% 988
2016
Q4 		– Sell
-5,070
Closed -$29K – 963
2016
Q3 		$29K Hold
5,070
– – ﹤0.01% 817
2016
Q2 		$32K Sell
5,070
-60
-1% -$479 ﹤0.01% 846
2016
Q1 		$43K Hold
5,130
– – ﹤0.01% 803
2015
Q4 		$52K Buy
5,130
+1,340
+35% +$13.6K ﹤0.01% 784
2015
Q3 		$45K Buy
3,790
+2,010
+113% +$31.9K ﹤0.01% 693
2015
Q2 		$35K Buy
+1,780
New +$36.9K ﹤0.01% 613
2013
Q4 		– Sell
-5,050
Closed -$235K – 750
2013
Q3 		$235K Buy
5,050
+540
+12% +$27.7K ﹤0.01% 446
2013
Q2 		$234K Buy
+4,510
New +$239K ﹤0.01% 457

Other funds holding PLX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SWP
Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s PLX Position: Q2 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Protalix BioTherapeutics (PLX) in Q2 2026, closing a stake of 207,275 shares — an estimated $450K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in PLX in Q2 2013 and held it in 17 quarters. The position peaked at $1.24M in Q1 2025. 102 funds tracked by Wall St. Rank hold PLX as of Q2 2026.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Protalix BioTherapeutics position as of Q2 2026 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 207,275 Protalix BioTherapeutics shares in Q2 2026, an estimated $450K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Protalix BioTherapeutics in Q2 2013 and held it in 17 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Protalix BioTherapeutics position peaked at $1.24M in Q1 2025.
  • 102 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2026, filed 13 Aug 2026.